Latest releases
What are you looking for?
 |
Latest Annual Report |
|
Latest teleconference presentation |
|
Financial calender |
|
Clinical references |
|
Investor kit |
|
Financial glossary |
Reports
Each year, Lundbeck produces a wide range of financial reports to inform the investment community, plus documents regarding the environmental status of our production sites. You’ll find them all right here. View all reportsOrder printed material |
Share information
There are many factors that contribute to the activity of Lundbeck's shares. Here are some documents and background facts that have proven useful to our shareholders and potential investors. |
Subscribe
Keep Updated. |
15-May-2008 |
Acting on its authorization to acquire up to 10% of its shares, Lundbeck's Supervisory Board has resolved to initiate a share buyback program. Under the program Lundbeck will buy own shares for an amount of up to DKK 6 billion, cf. stock exchange announcement number 166 dated 17 August 2005. The buyback program is expected to be completed by the end of 2008.
|
13-May-2008 |
Lundbeck today announced the launch of Circadin® for insomnia in Germany. Circadin® was approved by the European Commission on 29 June 2007, and Lundbeck expects to launch the product in another 14 markets during 2008.
|
Financial calendar
13 August 2008
12 November 2008
Share information
 | 127.25 DKK +2.25  Open details |
| 16-May-2008 | |
Investor Relations contacts
Palle Holm Olesen
Head of Investor Relations
Tel: +45 3643 2426
Mob: +45 3083 2426
Fax: +45 3643 8262
palo@lundbeck.com
Thomas Bay-Wedel
Investor Relations Officer
Tel: +45 3643 3980
Mob: +45 3083 3980
Fax: +45 3643 8262
tbw@lundbeck.com
H. Lundbeck A/S
Ottiliavej 9
DK-2500 Copenhagen Valby
Ottiliavej 9
DK-2500 Copenhagen Valby
Tel +45 36 30 13 11
Fax +45 36 30 19 40
Fax +45 36 30 19 40
The specialist in psychiatry and pioneer in neurology
Disclaimer & Privacy statement
Disclaimer & Privacy statement